FDA issues warning on endoscopes after injuries, death from infections

The U.S. Food and Drug Administration (FDA) has issued an alert due to a high-risk issue with certain endoscopes manufactured by Olympus. The FDA’s notice follows a letter the company sent to customers on December 18 after reports of 120 injuries and 1 death related to infections caused by the endoscopes. 

While no formal recall has been issued, these communications could be a precursor. The FDA said its late-December alert is part of the process for its Communications Pilot to Enhance the Medical Device Recall Program.

The issue appears to affect all lots of MAJ-891 endoscopes, with infections linked to an issue with the forceps and irrigation plug, which are difficult to clean and sanitize. Reprocessing these particular endoscopes is common, as they are reusable. If not disassembled before sterilization, microbes can remain alive, leading to illnesses such as sepsis and urinary tract infections, which have been serious enough to cause hospitalizations. 

Olympus MAJ-891 endoscopes FDA alert
Image provided by the FDA.

Olympus has advised providers to seek alternative endoscopes, due to the issues with properly reprocessing the MAJ-891. However, it added there are no alternative irrigation plugs for the scopes, meaning providers may have to replace the scopes outright. 

To avoid a replacement, Olympus is asking providers to ensure the scopes are completely disassembled before being cleaned and sanitized, in accordance with the device’s instructions. They’re also recommending the biopsy valve be inspected before each use to ensure there is no damage or corrosion. 

The affected scopes all share a unique device identifier (UDI): 04953170063114. 

Any questions or reports of adverse reactions should be addressed to Olympus by calling its Technical Assistance Center at 800-848-9024, option 1. 

The full recall notice—including the full list of scopes covered under this alert—can be found by clicking here

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.